Novo Nordisk CEO: Semaglutide could create serious obesity treatment market

Come summer, Novo Nordisk will know whether semaglutide can be used as obesity treatment, and CEO Lars Fruergaard Jørgensen says this approval has potential to change the market for obesity treatment.

Photo: Valdemar Ren

Novo Nordisk has great expectations for the potential launch of its drug, semaglutide, to treat severe obesity.

According to Novo Nordisk President & CEO Lars Fruergaard Jørgensen, the obesity treatment market may be facing an actual game changer, if the firm successfully obtains the necessary approval for using semaglutide as a medicine against obesity this year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Further reading

Related articles

Latest news

See all jobs